新型帕利珠单抗预防方案对先天性心脏病患儿呼吸道合胞病毒感染的多中心疗效研究
本研究评估了在无明确呼吸道合胞病毒季节性的亚热带地区,一种新型每月帕利珠单抗预防方案对血流动力学显著先天性心脏病(hsCHD)患儿的效果。多中心研究纳入747例治疗组和809例对照组,结果显示治疗组呼吸道合胞病毒住院率匹配前后分别降低53%和49%(P=.009和.029),住院天数和重症监护入住率也降低,发绀型hsCHD患者效果更显著。
要点
- 每月帕利珠单抗方案使hsCHD患儿呼吸道合胞病毒住院率降低53%(匹配前)和49%(匹配后)。
- 治疗组住院天数和重症监护入住率也相应降低。
- 发绀型hsCHD患者中该方案效果更突出。
核心结论
- 通过新型每月方案进行帕利珠单抗预防可有效减少hsCHD患者呼吸道合胞病毒相关住院。
研究设计与样本
- 多中心研究,比较2010至2016年prepalivizumab、过渡期和postpalivizumab期间hsCHD患者呼吸道合胞病毒住院趋势,并设治疗组和倾向匹配对照组。
- 研究组747例,对照组809例,男女比836:720,发绀型CHD占42.9%,CHD诊断平均年龄32.9天。
主要发现
- 与对照组相比,匹配前呼吸道合胞病毒住院率降低53%(P=.009),匹配后降低49%(P=.029)。
- 治疗组住院天数和重症监护入住率也类似降低。
- 发绀型hsCHD患者中方案效果更显著。
- 年度呼吸道合胞病毒相关住院率从prepalivizumab期的4.8%降至palivizumab期的2.0%(P=.038)。
关键数值与推荐
- 自2013年7月起,国家健康保险计划对选定1岁以下hsCHD患者报销新型每月帕利珠单抗预防方案。
临床怎么用
- 在无明确呼吸道合胞病毒季节性的亚热带地区,可考虑对1岁以下hsCHD患者采用新型每月帕利珠单抗预防方案以降低呼吸道合胞病毒住院风险。
- 发绀型hsCHD患者可能从该预防方案中获益更明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the efficacy of a novel palivizumab protocol for hemodynamically significant congenital heart disease (hsCHD) in subtropical areas without clear respiratory syncytial virus seasonality. STUDY DESIGN: Since July 2013, the National Health Insurance program has provided reimbursement for palivizumab prophylaxis with a novel monthly protocol in selected patients with hsCHD under 1 year of age. We performed a multicenter study to assess the trend of respiratory syncytial virus hospitalizations in patients with hsCHD from 2010 to 2016 during the prepalivizumab, transition, and postpalivizumab periods, and compared treatment and propensity-matched control groups. RESULTS: A total of 747 patients were enrolled in the study group and 809 in the control group. The male:female was 836:720. Cyanotic CHD was observed in 42.9% of patients. The mean age at diagnosis of CHD was 32.9 days. After 516 685 patient-days of follow-up and a mean of 3.9 doses of palivizumab in the treatment group, respiratory syncytial virus hospitalization rates decreased by 53% and 49% before and after match compared with the control group (P = .009 and .029, respectively). Hospitalization days and intensive care unit admission rate also decreased similarly in the treatment group. The efficacy of this protocol was more prominent in patients with cyanotic hsCHD. The annual respiratory syncytial virus-associated hospitalization rates also decreased significantly from the prepalivizumab to the palivizumab period (from 4.8% to 2.0%; P = .038). CONCLUSION: Palivizumab prophylaxis through the novel monthly protocol for patients with hsCHD is effective in reducing respiratory syncytial virus-related hospitalizations.
引用
- Chiu SN, Wang JN, Fu YC, et al. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study. J Pediatr. 2018. PMID: 29395174. doi:10.1016/j.jpeds.2017.11.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。